Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin in Patients With Cancer-Associated Thrombosis: A Meta-Analysis of Randomized Controlled Trials.

Cancer-associated thrombosis (CAT) is a significant cause of morbidity and mortality in patients with cancer. Determining the optimal anticoagulant remains a clinical challenge. This meta-analysis aimed to compare the efficacy and safety of direct oral anticoagulants (DOACs) and low-molecular-weight heparin (LMWH) for CAT treatment. We systematically searched databases for randomized controlled trials (RCTs) comparing DOACs and LMWH in patients diagnosed with CAT. Efficacy outcomes were recurrent venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE). Safety outcomes comprised total bleeding, major bleeding, clinically relevant nonmajor bleeding (CRNMB), and all-cause mortality. We calculated incidence risk ratios (IRRs) with 95% confidence intervals (CIs) using a random-effects model. Subgroup analyses were conducted based on administered DOAC type. We identified 10 RCTs with 4713 participants (mean age 64.63 years, 50.58% male), including 2390 receiving DOACs and 2323 receiving LMWH. Compared to LMWH, the DOACs group demonstrated a statistically significant reduction in the incidence of VTE (IRR = 0.66, 95% CI 0.56 to 0.79). Total bleeding (IRR = 1.10, 95% CI 0.80;1.50) and mortality (IRR = 1.00, 95% CI, 0.89-1.12) did not differ significantly. Sensitivity analyses of studies with >100 participants and 6-month follow-up were consistent with overall results. In conclusion, DOACs were more effective than LMWH in reducing the risk of recurrent VTE and DVT in patients with CAT, with comparable safety profiles. The improved efficacy of DOACs positions them as a potentially advantageous therapeutic option for this patient population. Further research is warranted to optimize DOAC use in different cancer types and patient subgroups.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Cancer-associated thrombosis (CAT) is a significant cause of morbidity and mortality in patients with cancer. Determining the optimal anticoagulant remains a clinical challenge.

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

More peer-reviewed studies in Klinische Studien.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial — Abtahi-Forooshani M et al. (2026)
• Reverse Sural Flap Venous Congestion Successfully Managed With Enoxaparin in a Male Patient With a Traumatic Foot Crush Injury: A Case Report — Velasco-Bustamante J et al. (2026)
• Investigation of the therapeutic effects of medicinal leech treatment on lower extremity ischemia-reperfusion injury — Ünal K et al. (2026)
• Efficacy of Medicinal Leech Therapy in Diverse Clinical Applications: A Comprehensive Study from Azerbaijan — Farzali S et al. (2025)
• HIRUDOTHERAPY IN RECONSTRUCTIVE SURGERY: CASE-REPORTS AND REVIEW — Heinz P et al. (2020)
• Hirudotherapy Efficacy and Complications in the Management of Microsurgical Breast Reconstruction: A Systematic Review — Foppiani J et al. (2024)
• Hirudotherapy in Wound Healing — Nair H et al. (2022)

Browse all ASH-analysed research →